Albert Qin

SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia

Srđan Verstovšek, Norio Komatsu, Harinder Gill et al. · Future Oncology · 2022 · 38 citations · Full text

Essential Thrombocythemia, High-risk Essential Thrombocythemia, Immunology +17

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study

Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh et al. · International Journal of Hematology · 2022 · 34 citations

Polycythemia Vera, Ropeginterferon Alfa-2b, Hematology +3

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

Yi‐Wen Huang, Chao‐Wei Hsu, Sheng‐Nan Lu et al. · Hepatology International · 2020 · 32 citations · Full text

Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration

Narihisa Miyachi, Oleh Zagrijtschuk, Lisa Kang et al. · Clinical Drug Investigation · 2021 · 31 citations

Caucasian Subjects, Ropeginterferon Alfa-2b, Medicine +3

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Albert Qin, Raymond Urbanski, Lennex Hsueh‐Lin Yu et al. · Frontiers in Oncology · 2023 · 31 citations · Full text

Hematological Malignancy, Thrombosis, Ropeginterferon Alfa-2b +15